Comparable stake leader
Redmile Group, LLC
SEC ownership of ADC Therapeutics SA
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001771910.
Disclosed value leader
Redmile Group, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- ADCT on NYSE
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Redmile Group, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Redmile Group, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001771910
- Issuer location
- Epalinges, Switzerland
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ADC Therapeutics SA (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Redmile Group, LLC
Disclosed value leader
Redmile Group, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 9.9%
13D/G row: Redmile Group, LLC
Showing 1-8 of 50 holder rows.
Quick read
Redmile Group, LLC leads the comparable SEC ownership view at 9.9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Redmile Group, LLC's linked filing trail.
Comparable ownership
Top 5
Redmile Group, LLC
9.9%
HPWH TH AG
9.6%
TCG Crossover GP II, LLC
9.2%
Prosight Management, LP
6.8%
BlackRock, Inc.
5.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Redmile Group, LLC |
3/4/5
13D/G
10%+ Owner
|
9.9%
from 13D/G
|
$105,194,110
30,624,334 shares
mixed-class rows
|
+$10,363,653 | 31 Mar 2026 |
| HPWH TH AG |
13D/G
Dr. Hans-Peter Wild
|
9.6%
|
$14,291,858
9,788,944 shares
|
$0 | 15 May 2025 |
| TCG Crossover GP II, LLC |
13D/G
|
9.2%
|
$42,143,648
11,390,175 shares
|
$0 | 27 Oct 2025 |
| Prosight Management, LP |
13D/G
|
6.8%
|
$31,366,151
8,477,338 shares
|
+$4,743,267 | 31 Dec 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.4%
from 13D/G
|
$7,511,500
7,020,093 shares
|
— | 30 Jun 2026 |
| Oaktree Capital Group Holdings GP, LLC |
13D/G
Oaktree Fund Administration, LLC
|
4.1%
|
$18,693,764
4,673,441 shares
|
$0 | 30 Sep 2025 |
| Point72 Asset Management, L.P. |
13D/G
|
4%
|
$18,554,083
5,014,617 shares
|
-$10,422,190 | 31 Dec 2025 |
| ORBIMED ADVISORS LLC |
13D/G
ORBIMED CAPITAL LLC
|
2.6%
|
$11,953,949
3,230,797 shares
|
-$765,959 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$28,909,027.
Buys
$29,999,993
Insiders: 1
Sells
$58,909,021
Insiders: 3
Net
-$28,909,027
Shares: -9,948,939
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 7,692,306
Shares: 17,641,245
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 17,641,245 | $0 | $58,909,021 | -$58,909,021 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 7,692,306 | 0 | $29,999,993 | $0 | +$29,999,993 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to ADC Therapeutics SA. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Redmile Group, LLC
Net 12M change
-$28,909,027
Latest report
30 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Redmile Group, LLC | 10%+ Owner | $105,194,110 | +$10,363,653 | +11% | Filing P/S | 31 Mar 2026 |
| Jeremy Green | 10%+ Owner | $75,194,118 | -$19,636,340 | -21% | Filing P/S | 31 Mar 2026 |
| RedCo II Master Fund, L.P. | 10%+ Owner | $75,194,118 | -$19,636,340 | -21% | Filing P/S | 31 Mar 2026 |
| Hans Peter Wild | 10%+ Owner | $14,291,858 | Mixed | 15 May 2025 | ||
| Ameet Mallik | Chief Executive Officer, Director | $10,499,216 | Mixed | 30 Jun 2026 | ||
| Jose Carmona | Chief Financial Officer | $3,517,785 | Mixed | 30 Jun 2026 | ||
| Mohamed Zaki | Chief Medical Officer | $3,361,188 | Mixed | 30 Jun 2026 | ||
| Peter J. Graham | Chief Legal Officer | $3,156,150 | Mixed | 30 Jun 2026 | ||
| Peter Hug | Director | $987,540 | Mixed | 01 Jun 2026 | ||
| Viviane Monges | Director | $699,176 | Mixed | 01 Jun 2026 | ||
| Victor Sandor | Director | $527,572 | Mixed | 01 Jun 2026 | ||
| Jean-Pierre Bizzari | Director | $522,382 | Mixed | 01 Jun 2026 | ||
| Lisa Michelle Kallebo | Chief Accounting Officer | $511,613 | Mixed | 13 Feb 2026 | ||
| Ron Squarer | Director | $462,866 | Mixed | 01 Jun 2026 | ||
| Robert Azelby | Director | $423,018 | Mixed | 01 Jun 2026 | ||
| Timothy Coughlin | Director | $271,500 | Mixed | 01 Jun 2026 | ||
| Thomas Pfisterer | Other* | $253,892 | Mixed | 15 May 2025 | ||
| Tyrell Rivers | Director | Mixed | 02 Jan 2024 |
Recent insider transactions for ADC Therapeutics SA
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mohamed Zaki | ADCT | Common Shares | Award | 31.3% | 213,900 | 896,317 | 30 Jun 2026 | Direct | ||
| Peter J. Graham | ADCT | Common Shares | Award | 35.6% | 221,100 | 841,640 | 30 Jun 2026 | Direct | ||
| Jose Carmona | ADCT | Common Shares | Award | 27.7% | 203,700 | 938,076 | 30 Jun 2026 | Direct | ||
| Ameet Mallik | ADCT | Common Shares | Award | 46.7% | 675,000 | 2,121,769 | 30 Jun 2026 | Direct | ||
| Robert Azelby | ADCT | Common Shares | Tax liability | -10% | -12,600 | 112,805 | 03 Jun 2026 | Direct | ||
| Ron Squarer | ADCT | Common Shares | Tax liability | -11% | -15,196 | 123,431 | 03 Jun 2026 | Direct | ||
| Victor Sandor | ADCT | Common Shares | Tax liability | -8.22% | -12,600 | 140,686 | 03 Jun 2026 | Direct | ||
| Viviane Monges | ADCT | Common Shares | Tax liability | -1.37% | -2,596 | 186,447 | 03 Jun 2026 | Direct | ||
| Peter Hug | ADCT | Common Shares | Tax liability | -0.81% | -2,156 | 263,344 | 03 Jun 2026 | Direct | ||
| Jean-Pierre Bizzari | ADCT | Common Shares | Tax liability | -8.29% | -12,600 | 139,302 | 03 Jun 2026 | Direct | ||
| Timothy Coughlin | ADCT | Common Shares | Tax liability | -14.8% | -12,600 | 72,400 | 03 Jun 2026 | Direct | ||
| Robert Azelby | ADCT | Common Shares | Award | 56% | 45,000 | 125,405 | 01 Jun 2026 | Direct | ||
| Ron Squarer | ADCT | Common Shares | Award | 48.1% | 45,000 | 138,627 | 01 Jun 2026 | Direct | ||
| Victor Sandor | ADCT | Common Shares | Award | 41.6% | 45,000 | 153,286 | 01 Jun 2026 | Direct | ||
| Viviane Monges | ADCT | Common Shares | Award | 31.2% | 45,000 | 189,043 | 01 Jun 2026 | Direct | ||
| Peter Hug | ADCT | Common Shares | Award | 20.4% | 45,000 | 265,500 | 01 Jun 2026 | Direct | ||
| Jean-Pierre Bizzari | ADCT | Common Shares | Award | 42.1% | 45,000 | 151,902 | 01 Jun 2026 | Direct | ||
| Timothy Coughlin | ADCT | Common Shares | Award | 112.5% | 45,000 | 85,000 | 01 Jun 2026 | Direct | ||
| Redmile Group, LLC | ADCT | Common Stock | Sale | -19.8% | $8,294,201 | $3.28 | -2,529,491 | 10,265,297 | 02 Apr 2026 | Direct |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -19.8% | $8,294,201 | $3.28 | -2,529,491 | 10,265,297 | 02 Apr 2026 | Direct |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -19.8% | $8,294,201 | $3.28 | -2,529,491 | 10,265,297 | 02 Apr 2026 | Direct |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -17.2% | $8,638,545 | $3.28 | -2,634,506 | 12,666,731 | 02 Apr 2026 | See Footnote |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -17.2% | $8,638,545 | $3.28 | -2,634,506 | 12,666,731 | 02 Apr 2026 | See Footnote |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -17.2% | $8,638,545 | $3.28 | -2,634,506 | 12,666,731 | 02 Apr 2026 | See Footnote |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.25% | $617,402 | $3.80 | -162,517 | 12,794,788 | 01 Apr 2026 | Direct |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.25% | $617,402 | $3.80 | -162,517 | 12,794,788 | 01 Apr 2026 | Direct |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.25% | $617,402 | $3.80 | -162,517 | 12,794,788 | 01 Apr 2026 | Direct |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.09% | $643,038 | $3.80 | -169,265 | 15,301,237 | 01 Apr 2026 | See Footnote |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.09% | $643,038 | $3.80 | -169,265 | 15,301,237 | 01 Apr 2026 | See Footnote |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.09% | $643,038 | $3.80 | -169,265 | 15,301,237 | 01 Apr 2026 | See Footnote |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.43% | $706,903 | $3.75 | -188,407 | 12,957,305 | 31 Mar 2026 | Direct |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.43% | $706,903 | $3.75 | -188,407 | 12,957,305 | 31 Mar 2026 | Direct |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.43% | $706,903 | $3.75 | -188,407 | 12,957,305 | 31 Mar 2026 | Direct |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.25% | $736,251 | $3.75 | -196,229 | 15,470,502 | 31 Mar 2026 | See Footnote |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.25% | $736,251 | $3.75 | -196,229 | 15,470,502 | 31 Mar 2026 | See Footnote |
| Redmile Group, LLC | ADCT | Common Stock | Sale | -1.25% | $736,251 | $3.75 | -196,229 | 15,470,502 | 31 Mar 2026 | See Footnote |
| Lisa Michelle Kallebo | ADCT | Common Shares | Tax liability | -4.06% | -5,433 | 128,224 | 13 Feb 2026 | Direct | ||
| Lisa Michelle Kallebo | ADCT | Common Shares | Award | 88.9% | 62,900 | 133,657 | 13 Feb 2026 | Direct | ||
| Mohamed Zaki | ADCT | Common Shares | Tax liability | -3.48% | -24,603 | 682,417 | 13 Feb 2026 | Direct | ||
| Mohamed Zaki | ADCT | Common Shares | Award | 67.6% | 285,200 | 707,020 | 13 Feb 2026 | Direct | ||
| Peter J. Graham | ADCT | Common Shares | Tax liability | -5.09% | -33,294 | 620,540 | 13 Feb 2026 | Direct | ||
| Peter J. Graham | ADCT | Common Shares | Award | 82.1% | 294,800 | 653,834 | 13 Feb 2026 | Direct | ||
| Jose Carmona | ADCT | Common Shares | Tax liability | -3.4% | -25,880 | 734,376 | 13 Feb 2026 | Direct | ||
| Jose Carmona | ADCT | Common Shares | Award | 55.6% | 271,600 | 760,256 | 13 Feb 2026 | Direct | ||
| Ameet Mallik | ADCT | Common Shares | Tax liability | -6.66% | -103,231 | 1,446,769 | 13 Feb 2026 | Direct | ||
| Ameet Mallik | ADCT | Common Shares | Award | 138.5% | 900,000 | 1,550,000 | 13 Feb 2026 | Direct | ||
| Ameet Mallik | ADCT | Common Shares | Tax liability | -15% | -233,146 | 1,319,101 | 06 Dec 2025 | Direct | ||
| Mohamed Zaki | ADCT | Common Shares | Tax liability | -8.87% | -41,068 | 421,820 | 06 Dec 2025 | Direct | ||
| Lisa Michelle Kallebo | ADCT | Common Shares | Tax liability | -9.17% | -7,140 | 70,757 | 06 Dec 2025 | Direct | ||
| Peter J. Graham | ADCT | Common Shares | Tax liability | -12.1% | -49,508 | 359,034 | 06 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.